New Immunotherapy Treatment for Follicular Lymphoma Approved in Australia
In a significant advancement in cancer treatment, the Pharmaceutical Benefits Scheme (PBS) in Australia has listed Minjuvi® (tafasitamab), marking a new era for patients facing relapsed or refractory follicular lymphoma (R/R FL). This immunotherapy combines Minjuvi with rituximab and lenalidomide, making it the first chemotherapy-free option available for this challenging form of cancer.
Follicular lymphoma is a type of non-Hodgkin lymphoma that affects thousands of Australians, with approximately 1,500 new cases diagnosed each year. It is characterized by its slow progression but is notorious for relapses, often requiring patients to undergo multiple therapies over the course of their treatment journey.
The listing of Minjuvi on PBS is both timely and crucial, particularly given that it represents the first new therapy reimbursed for R/R FL in nearly a decade. This development follows recent approval by the Therapeutic Goods Administration (TGA) in April 2026, further supporting its significance for Australian patients. Dr. Philip Thompson, a Clinical Haematologist, emphasizes the importance of this new treatment option, particularly for those who have not responded to previous therapies.
In the pivotal Phase 3 inMIND clinical trial, patients receiving the Minjuvi combination demonstrated remarkable outcomes. Results revealed a 57% reduction in the risk of disease progression, relapse, or death compared to other therapies, translating to a meaningful improvement in progression-free survival. Patients using this regimen experienced a median progression-free survival of 22.4 months, highlighting its effectiveness and potential to transform treatment outcomes for those with this condition.
Minjuvi is a dual-targeted immunotherapy that engages the immune system to attack and eliminate malignant B-cells. Administered via intravenous (IV) infusion, it combines with oral lenalidomide and rituximab. This novel combination not only aids in controlling disease progression but also supports better long-term outcomes for patients suffering from follicular lymphoma.
As of August 1, 2026, Minjuvi will be available to eligible patients under the PBS, ensuring equitable access to this groundbreaking treatment. This initiative underscores Specialised Therapeutics' commitment to providing innovative therapies to enhance the lives of patients across Australia and the Asia-Pacific region.
Sharon Winton, CEO of Lymphoma Australia, expressed her optimism regarding the new treatment. With a chemotherapy-free regimen now funded, patients facing the trials of recurring follicular lymphoma have a valuable option. This significant milestone offers hope and meaning to patients and their families alike.
Minjuvi's PBS inclusion highlights a substantial advancement in immunotherapy treatments available for follicular lymphoma. As the medical community embraces these innovative strategies, patients with R/R FL are poised to benefit from a new era of targeted therapy that could significantly alter their treatment experience. For patients, discussing this option with healthcare professionals will be crucial in determining the most suitable treatment pathway. As Australia continues to break ground in cancer care, this listing represents a pivotal moment in the fight against follicular lymphoma.
Background on Follicular Lymphoma
Follicular lymphoma is a type of non-Hodgkin lymphoma that affects thousands of Australians, with approximately 1,500 new cases diagnosed each year. It is characterized by its slow progression but is notorious for relapses, often requiring patients to undergo multiple therapies over the course of their treatment journey.
The Significance of Minjuvi
The listing of Minjuvi on PBS is both timely and crucial, particularly given that it represents the first new therapy reimbursed for R/R FL in nearly a decade. This development follows recent approval by the Therapeutic Goods Administration (TGA) in April 2026, further supporting its significance for Australian patients. Dr. Philip Thompson, a Clinical Haematologist, emphasizes the importance of this new treatment option, particularly for those who have not responded to previous therapies.
Clinical Trial Success
In the pivotal Phase 3 inMIND clinical trial, patients receiving the Minjuvi combination demonstrated remarkable outcomes. Results revealed a 57% reduction in the risk of disease progression, relapse, or death compared to other therapies, translating to a meaningful improvement in progression-free survival. Patients using this regimen experienced a median progression-free survival of 22.4 months, highlighting its effectiveness and potential to transform treatment outcomes for those with this condition.
How It Works
Minjuvi is a dual-targeted immunotherapy that engages the immune system to attack and eliminate malignant B-cells. Administered via intravenous (IV) infusion, it combines with oral lenalidomide and rituximab. This novel combination not only aids in controlling disease progression but also supports better long-term outcomes for patients suffering from follicular lymphoma.
Access and Availability
As of August 1, 2026, Minjuvi will be available to eligible patients under the PBS, ensuring equitable access to this groundbreaking treatment. This initiative underscores Specialised Therapeutics' commitment to providing innovative therapies to enhance the lives of patients across Australia and the Asia-Pacific region.
A Voice from the Lymphoma Community
Sharon Winton, CEO of Lymphoma Australia, expressed her optimism regarding the new treatment. With a chemotherapy-free regimen now funded, patients facing the trials of recurring follicular lymphoma have a valuable option. This significant milestone offers hope and meaning to patients and their families alike.
Conclusion
Minjuvi's PBS inclusion highlights a substantial advancement in immunotherapy treatments available for follicular lymphoma. As the medical community embraces these innovative strategies, patients with R/R FL are poised to benefit from a new era of targeted therapy that could significantly alter their treatment experience. For patients, discussing this option with healthcare professionals will be crucial in determining the most suitable treatment pathway. As Australia continues to break ground in cancer care, this listing represents a pivotal moment in the fight against follicular lymphoma.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.